Despite new therapeutic approaches such as the optimization of common cytotoxic agents and the testing of novel drugs such as epidermal growth factor receptor (EGFR) and poly-ADP-ribose-polymerase-1 inhibitors, there is still a strong need for novel therapeutic targets for this aggressive breast cancer subtype. Here, EGFR is linked to breast carcinoma.